Investment analysts at William Blair began coverage on shares of Hinge Health (NYSE:HNGE - Get Free Report) in a report issued on Monday, MarketBeat.com reports. The firm set an "outperform" rating on the stock.
Other equities analysts have also issued research reports about the company. Canaccord Genuity Group initiated coverage on Hinge Health in a research note on Monday. They set a "buy" rating and a $52.00 price target on the stock. Bank of America began coverage on Hinge Health in a report on Monday. They issued a "buy" rating and a $42.00 price target for the company. Truist Financial initiated coverage on shares of Hinge Health in a research note on Monday. They set a "buy" rating and a $48.00 price objective for the company. Evercore ISI assumed coverage on shares of Hinge Health in a research note on Monday. They set an "outperform" rating and a $50.00 price objective for the company. Finally, Stifel Nicolaus assumed coverage on Hinge Health in a research report on Monday. They issued a "buy" rating and a $48.00 price objective on the stock. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Hinge Health currently has an average rating of "Moderate Buy" and an average target price of $46.00.
Read Our Latest Report on HNGE
Hinge Health Stock Performance
Hinge Health stock opened at $34.76 on Monday. Hinge Health has a 1 year low of $33.42 and a 1 year high of $43.80.
Hinge Health Company Profile
(
Get Free Report)
Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Hinge Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hinge Health wasn't on the list.
While Hinge Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
